Cargando…

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study

BACKGROUND: To characterize the clinicopathological features and evaluate the neoadjuvant chemotherapy (NACT) efficacy of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer. METHODS: A total of 905 breast cancer patients who received 4 cycles of thrice-weekly standard NA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Lingfeng, Li, Zhenghang, Jiang, Linshan, Shu, Xiujie, Xu, Yingkun, Liu, Shengchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810386/ https://www.ncbi.nlm.nih.gov/pubmed/36605428 http://dx.doi.org/10.3389/fonc.2022.999716

Ejemplares similares

Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
por: Tang, Lingfeng, et al.
Publicado: (2022)

The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
por: Li, Fu, et al.
Publicado: (2023)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study
por: Fei, Kailun, et al.
Publicado: (2023)

The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy: a retrospective study based on real-world data
por: Dai, Yuran, et al.
Publicado: (2023)

Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
por: Lv, Zhi-Dong, et al.
Publicado: (2022)

Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy
por: Shu, Dan, et al.
Publicado: (2022)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2020)

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis
por: Debiasi, Márcio, et al.
Publicado: (2018)

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022)

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
por: Díaz-Redondo, Tamara, et al.
Publicado: (2019)

Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis
por: Mao, Xiaoyun, et al.
Publicado: (2022)

Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study
por: Xiang, Xiaosong, et al.
Publicado: (2023)

Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
por: Wang, Yihua, et al.
Publicado: (2021)

Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer
por: Shang, Jiuyan, et al.
Publicado: (2023)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
por: Pöschke, Patrik, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress
por: Chen, Yushi, et al.
Publicado: (2023)

Human clinical trial using diagnostic ultrasound and microbubbles to enhance neoadjuvant chemotherapy in HER2- negative breast cancer
por: Zhou, Biqiang, et al.
Publicado: (2022)

PTCH1 and CTNNB1 emerge as pivotal predictors of resistance to neoadjuvant chemotherapy in ER+/HER2- breast cancer
por: Ozcan, Gulnihal
Publicado: (2023)

Development and testing of a random forest-based machine learning model for predicting events among breast cancer patients with a poor response to neoadjuvant chemotherapy
por: Jin, Yudi, et al.
Publicado: (2023)

Cisplatin-based chemotherapy for the treatment of metastatic collecting duct carcinomas: A real-world, retrospective analysis
por: Rizzo, Mimma, et al.
Publicado: (2022)

A Novel Combined Nomogram Model for Predicting the Pathological Complete Response to Neoadjuvant Chemotherapy in Invasive Breast Carcinoma of No Specific Type: Real-World Study
por: Zhu, Xuelin, et al.
Publicado: (2022)

Machine Learning-Based Radiomics Nomogram Using Magnetic Resonance Images for Prediction of Neoadjuvant Chemotherapy Efficacy in Breast Cancer Patients
por: Chen, Shujun, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients
por: Wang, Yihua, et al.
Publicado: (2021)

Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
por: Ma, Xiangmin, et al.
Publicado: (2022)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study
por: Wang, Shu, et al.
Publicado: (2023)

Breast Metastasis From Rectal Signet-Ring Cell Carcinoma: A Case Report and Review of Literature
por: Dai, Yuran, et al.
Publicado: (2022)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
por: Dowling, Gavin P., et al.
Publicado: (2023)

Association of serum reproductive hormones changes after neoadjuvant chemotherapy with hormone receptors expression alterations and survival outcomes in breast cancer
por: Lan, Ailin, et al.
Publicado: (2022)

Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy
por: Song, Yu-Chun, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study
por: Zhou, Meirong, et al.
Publicado: (2022)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
por: Fabbri, Agnese, et al.
Publicado: (2023)

Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World
por: Yu, Xingfei, et al.
Publicado: (2021)

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
por: Kaufman, Peter A., et al.
Publicado: (2023)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9ib9gftksugnd5eenns1ktrboq